BCL2 and neoplasm: First characterized in hematological cancers, it is now recognized that alterations in the BCL-2 family are also frequent in solid tumors and that failed intrinsic (mitochondrial) apoptosis facilitates tumor survival throughout the oncogenic process [4,5].